Medication Summary

See Special Concerns and Surgical Care.

Class Summary

Reduce the incidence of rebleeds in the setting of hyphema.

Aminocaproic acid (Amicar)

View full drug information

Inhibits fibrinolysis via inhibition of plasminogen activator substances; to a lesser degree, through antiplasmin activity.

Main problem is that the thrombi that form during treatment are not lysed, and effectiveness is uncertain.

Class Summary

Reduce the incidence of rebleeds in the setting of hyphema.

Prednisolone 1% (Pred Forte)

View full drug information

Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

Prednisone (Deltasone, Orasone, Meticorten)

View full drug information

May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Questions

Feroze KB, Azevedo AM. Retinopathy Hemoglobinopathies. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].
Salinas Cisneros G, Thein SL. Research in Sickle Cell Disease: From Bedside to Bench to Bedside. Hemasphere. 2021 Jun. 5 (6):e584. [QxMD MEDLINE Link].
Ingram VM. Sickle-cell anemia hemoglobin: the molecular biology of the first "molecular disease"--the crucial importance of serendipity. Genetics. 2004 May. 167 (1):1-7. [QxMD MEDLINE Link].
Moussa O, Chen RWS. Hemoglobinopathies: ocular manifestations in children and adolescents. Ther Adv Ophthalmol. 2021 Jan-Dec. 13:25158414211022882. [QxMD MEDLINE Link].
Goldberg MF. Classification and pathogenesis of proliferative sickle retinopathy. Am J Ophthalmol. 1971 Mar. 71 (3):649-65. [QxMD MEDLINE Link].
Brousse V, Rees DC. Sickle cell disease: More than a century of progress. Where do we stand now?. Indian J Med Res. 2021 Jan. 154 (1):4-7. [QxMD MEDLINE Link]. [Full Text].
American Society of Hematology. Sickle Cell Trait. American Society of Hematology. Available at https://www.hematology.org/education/patients/anemia/sickle-cell-trait. Accessed: December 13, 2021.
Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011 Dec. 41 (6 Suppl 4):S398-405. [QxMD MEDLINE Link].
What You Should Know About Sickle Cell Trait. National Center on Birth Defects and Developmental Disorders, Division of Blood Disorders, Centers for Disease and Prevention (CDC). Available at https://www.cdc.gov/ncbddd/sicklecell/documents/scd%20factsheet_sickle%20cell%20trait.pdf. Accessed: December 14, 2021.
Nia J, Lam WC, Kleinman DM, Kirby M, Liu ES, Eng KT. Retinopathy in sickle cell trait: does it exist?. Can J Ophthalmol. 2003 Feb. 38 (1):46-51. [QxMD MEDLINE Link].
Sickle Cell Retinopathy. American Society of Retina Specialists. Available at https://www.asrs.org/patients/retinal-diseases/41/sickle-cell-retinopathy. Accessed: December 13, 2021.
Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. 2011 May-Jun. 31 (3):289-93. [QxMD MEDLINE Link].
Sedrak A, Kondamudi NP. Sickle Cell Disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. [Full Text].
Leveziel N, Bastuji-Garin S, Lalloum F, Querques G, Benlian P, Binaghi M, et al. Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine (Baltimore). 2011 Nov. 90(6):372-8. [QxMD MEDLINE Link].
Cho M, Kiss S. Detection and monitoring of sickle cell retinopathy using ultra wide-field color photography and fluorescein angiography. Retina. 2011 Apr. 31(4):738-47. [QxMD MEDLINE Link].
Dell'Arti L, Barteselli G, Riva L, Carini E, Graziadei G, Benatti E, et al. Sickle cell maculopathy: Identification of systemic risk factors, and microstructural analysis of individual retinal layers of the macula. PLoS One. 2018. 13 (3):e0193582. [QxMD MEDLINE Link].
Lott PW, McKibbin M. Prevalence of Dark without Pressure and Angioid Streaks in Sickle Cell Disease. Ophthalmic Surg Lasers Imaging Retina. 2021 Nov. 52 (11):620-622. [QxMD MEDLINE Link].
Aessopos A, Voskaridou E, Kavouklis E, et al. Angioid streaks in sickle-thalassemia. Am J Ophthalmol. 1994 May 15. 117(5):589-92. [QxMD MEDLINE Link].
Brazier DJ, Gregor ZJ, Blach RK, Porter JB, Huehns ER. Retinal detachment in patients with proliferative sickle cell retinopathy. Trans Ophthalmol Soc U K. 1986. 105 ( Pt 1):100-5. [QxMD MEDLINE Link].
Jampol LM, Green JL Jr, Goldberg MF, et al. An update on vitrectomy surgery and retinal detachment repair in sickle cell disease. Arch Ophthalmol. 1982 Apr. 100(4):591-3. [QxMD MEDLINE Link].
Sickle Cell Trait and Glaucoma Post-Hyphema: Tips to Protect Your Patient’s Vision. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/ncbddd/sicklecell/documents/fs_glaucoma_prov.pdf. Accessed: December 14, 2021.
Walkden A, Griffin B, Cheng C, Dhawahir-Scala F. Gross anterior segment ischaemia following vitreoretinal surgery for sickle-cell retinopathy. BMJ Case Rep. 2019 Jan 29. 12 (1):[QxMD MEDLINE Link].
Jin J, Kandula V, Miller RE. Monitoring retinal pathology and cerebral injury in sickle cell disease using spectral-domain optical coherence tomography in pediatric patients. Pediatr Blood Cancer. 2021 Jul. 68 (7):e29028. [QxMD MEDLINE Link].
Jampol LM. Vitrectomy surgery in proliferative sickle retinopathy. Am J Ophthalmol. 1987 Nov 15. 104(5):553-4. [QxMD MEDLINE Link].
Morgan CM, D'Amico DJ. Vitrectomy surgery in proliferative sickle retinopathy. Am J Ophthalmol. 1987 Aug 15. 104(2):133-8. [QxMD MEDLINE Link].
Pulido JS, Flynn HW Jr, Clarkson JG, et al. Pars plana vitrectomy in the management of complications of proliferative sickle retinopathy. Arch Ophthalmol. 1988 Nov. 106(11):1553-7. [QxMD MEDLINE Link].
Myint KT, Sahoo S, Thein AW, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev. 2015 Oct 9. CD010790. [QxMD MEDLINE Link].
Rednam KR, Jampol LM, Goldberg MF. Scatter retinal photocoagulation for proliferative sickle cell retinopathy. Am J Ophthalmol. 1982 May. 93(5):594-9. [QxMD MEDLINE Link].
Farber MD, Jampol LM, Fox P, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol. 1991 Mar. 109(3):363-7. [QxMD MEDLINE Link].
Kimmel AS, Magargal LE, Stephens RF, et al. Peripheral circumferential retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy. An update. Ophthalmology. 1986 Nov. 93(11):1429-34. [QxMD MEDLINE Link].
Jacobson MS, Gagliano DA, Cohen SB, et al. A randomized clinical trial of feeder vessel photocoagulation of sickle cell retinopathy. A long-term follow-up. Ophthalmology. 1991 May. 98(5):581-5. [QxMD MEDLINE Link].
Hanscom TA. Indirect treatment of peripheral retinal neovascularization. Am J Ophthalmol. 1982 Jan. 93(1):88-91. [QxMD MEDLINE Link].
Nasrullah A, Kerr NC. Sickle cell trait as a risk factor for secondary hemorrhage in children with traumatic hyphema. Am J Ophthalmol. 1997 Jun. 123(6):783-90. [QxMD MEDLINE Link].
Acheson RW, Ford SM, Maude GH, et al. Iris atrophy in sickle cell disease. Br J Ophthalmol. 1986 Jul. 70(7):516-21. [QxMD MEDLINE Link].
Andreoli TE, et al. Disorder of red cells. Cecil's Essentials of Medicine. 4th ed. 1997. 383-7.
Asdourian GK. Sickle cell retinopathy. Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 1994. Vol 2: 1006-1018.
Beutler E. Disorders of hemoglobin. Fauci AS, et al, eds. Harrison's Principle of Internal Medicine. 14th ed. 1998. 645-652.
Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997 Sep 11. 337(11):762-9. [QxMD MEDLINE Link].
Charache S. Eye disease in sickling disorders. Hematol Oncol Clin North Am. 1996 Dec. 10(6):1357-62. [QxMD MEDLINE Link].
Cohen SB, van Houten PA. Hemoglobinopathies. Ryan SJ, et al, eds. Retina. 2nd ed. 1994. 1465-1472.
Eagle RC. Retina-sickle hemoglobinopathy. Eye Pathology: An Atlas and Basic Text. 1999. 147, 153-4.
Farber MD, Fiscella R, Goldberg MF. Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Ophthalmology. 1991 Mar. 98(3):279-86. [QxMD MEDLINE Link].
Fekrat S, Lutty G, Goldberg M. Retina-Vitreous Macula. Guyer D, et al. Hemoglobinopathies. Vol 1. 1999. 438-458.
Fox PD, Dunn DT, Morris JS, et al. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol. 1990 Mar. 74(3):172-6. [QxMD MEDLINE Link].
Gagliano DA, Goldberg MF. The evolution of salmon-patch hemorrhages in sickle cell retinopathy. Arch Ophthalmol. 1989 Dec. 107(12):1814-5. [QxMD MEDLINE Link].
Goldbert MF. Duane's Clinical Ophthalmology. Tasman W and Jaeger EA. Sickle Cell Retinopathy. 1990. Vol 3.: 1-45.
Green WR. Retina: Systemic Diseases with Retinal Involvement. Spencer WH. Ophthalmic Pathology: An Atlas and Textbook. 1996. Vol 2: 1155-1160.
Jampol LM. Arteriolar occlusive diseases of the macula. Ophthalmology. 1983 May. 90(5):534-9. [QxMD MEDLINE Link].
Kark JA, Posey DM, Schumacher HR, et al. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med. 1987 Sep 24. 317(13):781-7. [QxMD MEDLINE Link].
Liebmann JM. Management of sickle cell disease and hyphema. J Glaucoma. 1996 Aug. 5(4):271-5. [QxMD MEDLINE Link].
Lubin BH. Sickle cell disease and the endothelium. N Engl J Med. 1997 Nov 27. 337(22):1623-5. [QxMD MEDLINE Link].
McLeod DS, Goldberg MF, Lutty GA. Dual-perspective analysis of vascular formations in sickle cell retinopathy. Arch Ophthalmol. 1993 Sep. 111(9):1234-45. [QxMD MEDLINE Link].
McLeod DS, Merges C, Fukushima A, et al. Histopathologic features of neovascularization in sickle cell retinopathy. Am J Ophthalmol. 1997 Oct. 124(4):455-72. [QxMD MEDLINE Link].
Palmer DJ, Goldberg MF, Frenkel M, et al. A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. Ophthalmology. 1986 Jan. 93(1):102-8. [QxMD MEDLINE Link].
Raichand M, Dizon RV, Nagpal KC, et al. Macular holes associated with proliferative sickle cell retinopathy. Arch Ophthalmol. 1978 Sep. 96(9):1592-6. [QxMD MEDLINE Link].
Serjeant GR. Sickle-cell disease. Lancet. 1997 Sep 6. 350(9079):725-30. [QxMD MEDLINE Link].
Siegel D. Diagnosis and treatment of sickle cell retinopathy. J Am Optom Assoc. 1988 Nov. 59(11):885-8. [QxMD MEDLINE Link].
Slavin ML, Barondes MJ. Ischemic optic neuropathy in sickle cell disease. Am J Ophthalmol. 1988 Feb 15. 105(2):212-3. [QxMD MEDLINE Link].
Stryer L. Oxygen-transporting proteins: myoglobin and hemoglobin. Biochemistry. 3rd ed. 1988. 143-173.
To KW, Nadel AJ. Ophthalmologic complications in hemoglobinopathies. Hematol Oncol Clin North Am. 1991 Jun. 5(3):535-48. [QxMD MEDLINE Link].
van Meurs JC. Evolution of a retinal hemorrhage in a patient with sickle cell-hemoglobin C disease. Arch Ophthalmol. 1995 Aug. 113(8):1074-5. [QxMD MEDLINE Link].

Media Gallery

of 0

Author

Brian A Phillpotts, MD Ophthalmologist, St Luke's Cataract and Laser Institute

Brian A Phillpotts, MD is a member of the following medical societies: American Academy of Ophthalmology, American Diabetes Association, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Association of University Professors of Ophthalmology

Disclosure: Nothing to disclose.

Coauthor(s)

Hon-Vu Quang Duong, MD Clinical Instructor of Ophthalmology and Ophthalmic Pathology, Westfield Eye Center; Senior Lecturer of Neurosciences (Anatomy and Physiology), Nevada State College

Hon-Vu Quang Duong, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Steve Charles, MD Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Hampton Roy, Sr, MD † Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Russell P Jayne, MD Vitreoretinal Surgeon, The Retina Center at Las Vegas

Russell P Jayne, MD is a member of the following medical societies: American Medical Association, American Society of Cataract and Refractive Surgery, American Society of Retina Specialists

Disclosure: Nothing to disclose.

Michael J Shapiro, MD Associate Professor, Vitreoretinal Service, Director, Eye Trauma Services, Department of Ophthalmology, University of Illinois at Chicago; Vitreoretinal Consultant, Pediatric Genetics and Birth Defects Clinic

Michael J Shapiro, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Society of Retina Specialists

Disclosure: Nothing to disclose.

Oswaldo Castro, MD Senior Advisor, Center for Sickle Cell Disease, Professor Emeritus of Medicine and Pediatrics, College of Medicine

Disclosure: Nothing to disclose.

Richard G Fiscella, PharmD, MPH Clinical Professor, Departments of Pharmacy and Ophthalmology, University of Illinois at Chicago

Disclosure: Nothing to disclose.